SCHEMBL5460935

SCHEMBL5460935

CNC(=O)COc1ccc2c(C(N)=O)c(NC(=O)C3CC3)sc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
FLT3 P36888 2/20 0.41
AURKA O14965 1/20 0.40
AURKB Q96GD4 1/20 0.40
KMT2A Q03164 2/20 0.38
TNIK Q9UKE5 2/20 0.38
POLB P06746 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAPK10 P53779 2/20 0.37
DYRK1A Q13627 2/20 0.37
UBE2N P61088 2/20 0.37
ABL1 P00519 1/20 0.37
PDE7A Q13946 1/20 0.37
PRNP P04156 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
PPARG P37231 1/20 0.36
HTT P42858 1/20 0.36
NCOA2 Q15596 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456020 0.89 MAPT (0.41) MAPTFLT3AURKAAURKBKMT2A
SCHEMBL5451020 0.88 ABL1 (0.49) MAPTFLT3AURKAAURKBKMT2A
SCHEMBL5453194 0.87 ALDH1A1 (0.41) MAPTFLT3AURKAAURKBKMT2A
SCHEMBL5453479 0.86 TNIK (0.37) MAPTFLT3AURKAAURKBKMT2A
SCHEMBL5451657 0.85 MEN1 (0.49) MAPTAURKAAURKBKMT2APOLB
SCHEMBL5455868 0.85 ABL1 (0.39) MAPTFLT3AURKAAURKBKMT2A
SCHEMBL5449196 0.85 ABL1 (0.50) MAPTFLT3AURKAAURKBTNIK
SCHEMBL5450710 0.84 MAPK10 (0.52) MAPTFLT3AURKAAURKBMAPK10
SCHEMBL5454161 0.84 FLT3 (0.41) MAPTFLT3AURKAAURKBTNIK
SCHEMBL5453440 0.83 GAA (0.44) MAPTKMT2APOLBTDP1PDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MAPT 21/4885FLT3 3509/4885AURKA 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.